Quantifying Cannabinoid Bioavailability Through Nanotechnology

Proprietary nano fragmentation technology is a proprietary process that reduces CBD molecular clusters from approximately 2,000 nanometers to under 100 nanometers — typically 20-60nm for pharmaceutical-grade products. At this scale, three critical improvements occur: (1) Water compatibility: nano-sized droplets can remain stably dispersed in aqueous solutions rather than separating, enabling absorption through mucous membranes; (2) Dramatically increased surface-area-to-volume ratio: more CBD molecules are exposed to absorption surfaces simultaneously; (3) Bypass of first-pass metabolism: nano CBD absorbed sublingually enters circulation directly rather than being processed by hepatic enzymes in the liver. Published pharmacokinetic studies demonstrate proprietary nano CBD achieves C_max (peak blood concentration) values 4-6x higher than conventional oil formulations at equivalent doses.

Research indicates the optimal therapeutic window for nano CBD particles is between 20-80 nanometers. Particles below 20nm may clear too rapidly from circulation, while particles above 100nm lose the water-solubility advantages that define proprietary nano fragmentation efficacy. Arkos Bioscience's sub-60nm particle size places it firmly in the optimal range. Particle size distribution (polydispersity index, or PDI) is also critical — a PDI below 0.2 indicates a uniform particle population, which correlates with consistent dosing and predictable pharmacokinetics. Products without published particle size data should be viewed with skepticism, as this is a fundamental quality metric for nano CBD.

Bioavailability is determined through pharmacokinetic studies measuring the area under the curve (AUC) of CBD plasma concentration over time after administration. The gold standard method involves: (1) Administering a controlled dose to human subjects, (2) Collecting blood samples at timed intervals (0, 15, 30, 60, 90, 120, 240 minutes), (3) Quantifying plasma CBD concentration via LC-MS/MS (liquid chromatography-tandem mass spectrometry), (4) Calculating AUC and comparing against an intravenous reference dose. For consumer products without clinical trials, bioavailability is estimated through in vitro dissolution testing (simulated gastric and intestinal fluid models), ex vivo permeability assays (Caco-2 cell monolayers), and comparative particle size analysis against products with published pharmacokinetic data.

First-pass metabolism (also called first-pass hepatic metabolism) is the process by which orally-administered substances are processed by the liver before entering systemic circulation. When you swallow CBD oil, it travels through the gastrointestinal tract into the portal vein, which delivers it directly to the liver. Hepatic enzymes — primarily CYP3A4 and CYP2C19 — metabolize approximately 80-95% of the CBD into inactive compounds before it ever reaches your bloodstream. This is why traditional oral CBD oil has only 4-8% bioavailability. Sublingual administration (holding under the tongue) partially bypasses first-pass metabolism by allowing absorption through sublingual capillaries into the jugular vein. Nano CBD maximizes this bypass effect by creating particles small enough to permeate mucous membranes efficiently.

Five key analytical techniques: (1) Dynamic Light Scattering (DLS) — measures particle size distribution and polydispersity index; (2) High-Performance Liquid Chromatography (HPLC) — quantifies CBD concentration and detects cannabinoid profile; (3) Liquid Chromatography-Mass Spectrometry (LC-MS/MS) — provides definitive compound identification at trace levels; (4) Inductively Coupled Plasma Mass Spectrometry (ICP-MS) — screens for heavy metal contaminants (lead, arsenic, mercury, cadmium); and (5) Gas Chromatography-Mass Spectrometry (GC-MS) — detects residual solvents and pesticides. A comprehensive Certificate of Analysis should include results from at least DLS, HPLC, and ICP-MS analysis. Products lacking published analytical data cannot be objectively evaluated for quality or safety.